NRx Pharmaceuticals Appoints Veteran Glenn Tyson to Drive Ketamine Product Launch
NRx Pharmaceuticals named Glenn Tyson as its first Chief Commercial Officer, leveraging his 25 years of industry experience and record of leading Indivior’s SUBLOCADE launch to 17 consecutive quarters of double-digit growth. The company is gearing up for anticipated approval of its preservative-free ketamine ANDA and an NDA submission to expand ketamine labeling for depression and suicidality while advancing its D-Cycloserine asset with Breakthrough Therapy Designation.
1. Appointment Details
On April 13, 2026, NRx Pharmaceuticals named Glenn Tyson as its first Chief Commercial Officer. Tyson brings 25 years of commercial and clinical experience, including 14 years at GSK and executive roles at Indivior, where he led the launch of SUBLOCADE® to 17 consecutive quarters of double-digit growth.
2. Commercial Ramp-Up
In his new role, Tyson will build market-access, distribution, sales and marketing capabilities to support the launch of the company’s preservative-free ketamine product and future pipeline therapies. This organizational expansion aims to ensure a successful commercialization strategy upon regulatory approvals.
3. Pipeline Development
NRx is awaiting FDA approval of its ANDA for preservative-free ketamine (NRX-100) and preparing an NDA under Fast Track Designation to expand labeling for severe depression and suicidality. The company is also advancing its oral D-Cycloserine asset (NRX-101), which holds Breakthrough Therapy Designation for enhancing transcranial magnetic stimulation in treating depression and suicidal ideation.